New strategies for solid tumor therapy: CAR-T combination therapy.
Are you ready?
Ever since reports that blood cancer response rates to T cells carrying chimeric antigen receptors (CARs) exceeded 80%, investors have been betting big on CAR-T cell approaches. In August, the first two therapies hit European markets in a head-to-head race to be the number one next-gen cancer therapy. But will CAR-T cell treatments lead the pack long term? Or will CAR-T for solid tumors leading the market future?
In this webinar
- China CAR-T development landscape and regulation
- Global CAR-T players
- CAR-T for solid tumors
- Interviews with one CAR-T biotech COO from Europe to share his views
Event details
|
DATE Wednesday June 24, 2020 VENUE Online Webex / Gotomeeting TIME 10am -11am (Berlin time) 4:00 PM - 5:00 PM (Beijing time) RSVP This is a complimentary event VIP tickets priority for Lingmed current clients Please RSVP by June 22, 2020 |
PRESENTERS Lingling Cao, CEO & Founder Dr Hank Wang, Medical advisor REGISTER +86 21 5386 3003 info@lingmed.net |
Agenda
| CET 10:00 - 10:10 | Linkedbio services & projects introductions | by LingLing Cao (English) |
| CET 10:10 - 10:40 | China CAR-T development landscape and regulation Global CAR-T players CAR-T for solid tumors | by Dr Hank Wang (Chinese) |
| CET 10:40 - 10:55 | Interviews with one CAR-T biotech COO from Europe to share his views | by Guest speaker (English) |
| CET 10:55 – 11:00 | Q&A | (English & Chinese) |
Presenters
 |
Lingling Cao CEO & Founder Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany |
 |
Hank Wang Medical advisor Dr Wang holds a PhD degree on Medicinal Chemistry from Peking University, has a Postdoc experience in University of Missouri-Saint Louis, and worked as a Postdoc Fellow in Auburn University. Hank Wang has more than 10 years’ experience in pharmaceuticals industry. Hank has worked as Vice President and President of R&D at Beijing Haiyan Pharmaceutical Co., Ltd. - Yangtze River Pharmaceutical Group. Dr Wang advises Lingmed on innovative assets evaluation for China market |